Comphya secures CHF 4.35M in Series A first tranche to support CaverSTIM clinical trials

25.02.2025 10:54, Rita Longobardi

Comphya, a leader in medical technology, has successfully closed the first tranche of its Series A1 funding round, raising CHF 4.35 million. The funding, consisting of a mix of convertible loans and newly raised equity, will help further develop CaverSTIM, the world's first implantable neuromodulator for erectile dysfunction. Clinical trials are already underway in Australia, Brazil, and the United States, and the funds will help continue advancing this innovative treatment, which has shown encouraging results.

Comphya, a leader in medical technology, has raised CHF 4.35 million in the first tranche of its Series A1 funding round. The amount, which combines converted convertible loans and fresh equity, will help strengthen the company's financial position and support the ongoing clinical trials for CaverSTIM, a novel implantable neuromodulator designed to treat erectile dysfunction. The trials, already taking place in Australia, Brazil, and the United States, have delivered promising results.

This funding will primarily support the continuation of clinical studies for CaverSTIM, a unique implantable neurostimulator aimed at restoring erectile function in patients who do not respond to oral medications, such as those recovering from prostate surgery. The device includes an implantable pulse generator (IPG) with a rechargeable battery and electronics that produce the necessary electrostimulation signals. Two electrodes connected to the IPG are placed in the pelvic cavity, where they stimulate the nerves responsible for penile erection, offering a potential solution to those in need.

Comphya has won Venture Kick, participated in Venture Leaders Life Sciences, and beem ranked among the TOP 100 Swiss Startups.


Comphya's team